Evidence map›Paper›PMID 37529400›Full record

ArticleCancer research communications2023

Characterizing the Immune Microenvironment and Neoantigen Landscape of Hürthle Cell Carcinoma to Identify Potential Immunologic Vulnerabilities.

Ian Ganly, Fengshen Kuo, Vladimir Makarov, Yiyu Dong, Ronald Ghossein, Bin Xu, Luc G T Morris, Timothy A Chan

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ian GanlyHuman Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7636-5426
Fengshen KuoHuman Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1797-2896
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-4104-5876
Yiyu DongHuman Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5391-4936
Ronald GhosseinDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2802-8489
Bin XuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4638-9835
Luc G T MorrisHuman Oncology and Pathology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4417-2280
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.ORCID 0000-0002-9265-0283
Memorial Sloan Kettering Cancer Center · USCleveland Clinic · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE in Thyroid CancerP50CA172012 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A · 2014 to 2018
$10.3M
TOWARDS PRECISION IMMUNO-ONCOLOGY: UNRAVELING THE GENOMIC DETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY EFFICACY AND RESISTANCER35CA232097 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAN, TIMOTHY AN-THY · 2018 to 2024
$7.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA172012NCI NIH HHS R35 CA232097
6 · The paper itself

Abstract

Hürthle cell carcinoma (HCC) is a rare type of thyroid cancer with high rates of distant metastasis and recurrence. Along with the scarcity of effective systemic therapies for HCC, these factors contribute to poor clinical outcomes. The immunologic features of HCC are poorly defined and response rates with immune checkpoint blockade have not been reported. A more comprehensive understanding of the immune landscape and factors that predict response to checkpoint inhibitors is needed. We performed RNA sequencing on 40 tumors to characterize the neoantigen landscape and immune microenvironment of HCC. We analyzed transcriptomic profiles, tumor-infiltrating immune cell populations, and measures of T-cell activation/dysfunction and correlated these to genetic features such as tumor mutation burden, neoantigen burden, mitochondrial mutations, and LOH from chromosomal uniparental disomy. Finally, immune profiles of patients with recurrence were compared with those of patients without recurrence. HCC tumors exhibited low levels of immune infiltration, with the more aggressive widely invasive phenotype associated with more immune depletion. There was a negative correlation between tumor mutation burden, neoantigen burden, programmed cell death ligand 1 (PD-L1) expression, and the immune infiltration score. HCC tumors that exhibited a global LOH from chromosomal uniparental disomy or haploidization had the lowest level of immune infiltration. HCC tumors that recurred displayed an immune-depleted microenvironment associated with global LOH and aerobic glycolysis. These findings offer new insights into the functional immune landscapes and immune microenvironment of HCC. Our data identify potential immunologic vulnerabilities for these understudied and often fatal cancers. Significance: The immune landscape of HCC is poorly defined and response rates to immunotherapy have not been reported. The authors found the immune microenvironment in HCC to be depleted. This immunosuppression is associated with a global LOH from haploidization and uniparental disomy, resulting in whole chromosome losses across the genome.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsB7-H1 AntigenHumansOxyphil CellsTumor MicroenvironmentUniparental DisomyB7-H1 Antigen

Identifiers

PMID37529400
PMCPMC10389111
OpenAlexW4383533961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.